MedTrace Logo

The Effects of Therapy With Teriparatide on Vascular Compliance and Osteoprotegerin/RANKL

NCT00347737 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2013-01-16

No results posted yet for this study

Summary

The purpose of this study is to determine what effect teriparatide will have on vascular (blood vessel) compliance and osteoprotegerin (bone fluid)and RANKL levels (bone cells).

Conditions

Interventions

DRUG

teriparatide

Teriparatide

Sponsors & Collaborators

  • University of Kansas

    collaborator OTHER

  • Leland Graves III, MD

    lead OTHER

Principal Investigators

  • Leland Graves, III, MD · University of Kansas Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2008-05-31
Completion
2008-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00347737 on ClinicalTrials.gov